Price
$5.10+60.38%Social Signal Score
Analyst Ratings
4 analysts52-week range
- Last close
- $5.10
- Off 52w high
- -66.7%
- 200-day average
- $8.35
- vs 200-day
- -38.9%
Revenue
$271.70M-4.77%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Devdatt Kurdikar
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 1,850
- Beta
- 0.85
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.31
Financials
Revenue
$271.70M-4.8%Net Income
$21.10M-80.0%EBITDA
$62.10M-56.7%Free Cash Flow
$40.70M-63.0%EPS (diluted)
$0.36-80.5%Shares Outstanding (diluted)
58.51M+2.7%Operating Expenses
$5.60MCash & Debt
$214.70MReturn of Capital
$9.30MRevenue by Segment (annual)
$171.70MDividend per Share
$0.01Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.08B | $95.40M | $1.64 |
| 2024 | $1.12B | $78.30M | $1.34 |
| 2023 | $1.12B | $70.40M | $1.23 |
| 2022 | $1.13B | $223.60M | $3.92 |
| 2021 | $1.17B | $414.80M | $7.31 |
| 2020 | $1.09B | $427.60M | $7.50 |
| 2019 | $1.11B | $432.00M | $7.58 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from EMBC's reported EPS growth of -22.5% a year over 6 years. Historical EPS growth of -23% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.73
- Implied price
- $6.53
- Return from $5.88
- 2.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.25 — -44.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -25.0% | -19.9% | -14.3% | -9.9% | -6.2% | -3.0% |
| -20.0% | -14.5% | -8.6% | -3.9% | 0.1% | 3.5% |
| -15.0% | -9.2% | -2.9% | 2.1% | 6.3% | 9.9% |
| -10.0% | -3.9% | 2.8% | 8.1% | 12.6% | 16.4% |
| -5.0% | 1.5% | 8.6% | 14.1% | 18.8% | 22.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·35d ago·Neutral
embecta to Participate in Investor Events In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
View source ↗ - Newsseekingalpha.com·42d ago·Positive
…mbecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize.
View source ↗ - Newsseekingalpha.com·59d ago·Positive
Embecta Corp. (EMBC) Q3 2026 Earnings Call Transcript Embecta Corp. (EMBC) Q3 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Nov 24(in 7 weeks)
Consensus estimate $0.31 per share
Typical surprise +6.1% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$0.56 vs $0.27beat
- Tue, May 5$0.27 vs $0.42miss
- Thu, Feb 5$0.71 vs $0.67beat
- Tue, Nov 25$0.50 vs $0.70miss
- Fri, Aug 8$1.12 vs $0.46beat
- Fri, May 9$0.70 vs $0.66beat
Estimates and results for EMBC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EMBC officers and directors.
- Bought
- $1.5m
- Sold
- $88k
13 trades
2 trades
- Morris Milton Mayosold
- Kurdikar Devdattbought
- Elguicze Jacobbought
- Mann Jeffrey Zbought
- Hombach Robert J.bought
- Melcher David Fbought
- Melcher David Fbought
- Morris Milton Mayosold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Tom Colehouse · OK04 · disclosed Apr 26, 2022 (25d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.